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ABSTRACT 
Dose-escalation to the prostate improves tumour control but at the expense of 
increased rectal toxicity. Modern imaging can be used to detect the most 
common site of recurrence, the intraprostatic lesion  (IPL), which has led to the 
concept of focussing dose-escalation to the IPL in order to improve the 
therapeutic ratio. Imaging must be able to detect lesions with adequate 
sensitivity and specificity to accurately delineate the IPL. This information must 
be carefully integrated into the radiotherapy planning process to ensure the dose 
is targeted to the IPL. This review will consider the role and challenges of multi-
parametric MRI (mp-MRI) and positron emission tomography computed 
tomography (PET-CT) in delineating a tumour boost to be delivered by external 
beam radiotherapy (EBRT). 
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Background – the rationale behind the intraprostatic boost 
 
Dose-escalation 
 
Increasing the dose to the prostate during radical radiotherapy (RT) has 
consistently shown improvement in biochemical control [1-6]. A meta-analysis 
showed that the postulated improvement in biochemical control rate at five 
years was an increase of 19.2% in high-risk patients between the dose ranges of 
70-80Gy [3]. However, dose-escalation to the whole prostate is associated with 
an increase in bladder and rectal toxicity [4-7].  
 
Patterns of recurrence 
 
Although prostate cancer tends to be multifocal, histopathology from 
prostatectomy specimens commonly reveals a larger focus or intraprostatic 
lesion (IPL), also referred to as the dominant intraprostatic lesion (DIL). Local 
recurrence following radical radiotherapy largely occurs at the site of the IPL [8-
10]. Cellini et al reported on 12 patients who had an intraprostatic recurrence, 
following EBRT and androgen deprivation therapy (ADT) [8]. For all 12 patients, 
clinical examination and imaging findings showed recurrence was at the site of 
the primary tumour.  Pucar et al reviewed pathology from salvage radical 
prostatectomy in 9 patients with locally recurrent disease [9]. Visual comparison 
of pathology, together with pre- and post-RT magnetic resonance imaging (MRI) 
showed that all significant recurrent lesions occurred at the site of the primary 
tumour.  
 
Therefore a higher dose to the IPL may reduce biochemical prostate-specific 
antigen (PSA) failure and it is suggested that improving local control may 
translate into a reduction in distant metastases [11]. 
 
Improved therapeutic ratio 
 
The demonstration of disease recurrence within the DIL has led to the proposal 
of boosting this region, whilst maintaining a standard dose to the rest of the 
prostate, in order to improve the therapeutic ratio [12]. The boost dose needs to 
be at least 80-90Gy in 2 Gray fractions, to reach the top of the tumour control 
probability (TCP) curve [3, 5]. The aim of treatment would be to increase the TCP 
without increasing the normal tissue complication probability (NTCP) for the 
bladder and rectum.  
 
Multifocality 
 
Prostatectomy specimens reveal the multifocality of prostate cancer [13] and 
when more than one tumour is identified on imaging, boosting several dominant 
nodules is technically possible [14]. The significance of smaller, incidental 
tumours however, is unclear. Noguchi et al reported that the secondary tumours 
identified following radical prostatectomy did not predict for biochemical failure 
[15]. In a disease where we know some low risk cancers can safely be observed 
[16, 17], stratification systems have been produced which help to determine 
intraprostatic disease which can be considered insignificant on template-
mapping biopsy procedures [18]. This is an important concept to consider when 
discussing IPL boost.  
 
Dose Painting 
 
Focal therapies to an IPL include the different techniques of external beam 
radiotherapy (EBRT), brachytherapy, high intensity focused ultrasound (HIFU) 
or cryotherapy. With radiotherapy techniques such as intensity modulated 
radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT), more 
complex dose distributions are possible, allowing an increase in dose to a 
particular volume, whilst limiting the dose to the organs at risk (OAR.) To deliver 
this dose accurately and improve the therapeutic ratio, prostate movement 
needs to be accounted for by image-guided radiotherapy (IGRT). The boost may 
be delivered sequentially, following standard treatment to the prostate, or as a 
simultaneous integrated boost (SIB). The optimal boost dose and radiotherapy 
planning method is unclear- this is beyond the scope of this review and will not 
be debated here. Most studies to date have used static field IMRT [14, 19-23]. 
Planning studies have also assessed VMAT [24-26] and SBRT techniques [27, 28]. 
Figure 1 shows an example of an IPL boost plan for Cyberknife delivered SBRT. 
 
 
 
Figure 1. An example of an IPL boost delivered using Cyberknife within the 
SPARC trial (NCT02145494). Purple shading represents prostate planning 
target volume (PTV), green shading represents IPL boost 
 
Also unclear is which groups of patients would benefit from an intraprostatic 
boost. Given the excellent control rates seen from studies such as the CHHiP trial 
[29], it may be that only higher risk patients will benefit from an intraprostatic 
boost.  
 
Identification of IPL 
 
Although imaging techniques have previously been reviewed for detection of an 
IPL, whether an image is sufficient to accurately define the tumour boundary is a 
separate question. An accurate IPL boost involves several stages, from optimal 
imaging, accurately transferring this information to the planning CT, correct 
identification and delineation of the lesion, and then delivering the radiotherapy 
as intended.  
 
In this article, we will be looking at the use of imaging when delineating a boost 
for EBRT modalities, specifically concentrating on multiparametric MRI (mp-
MRI) and positron emission tomography (PET). For each of these, we consider 
the limitations, practicalities and challenges of IPL delineation under the 
following sections 
 Type of imaging 
 Limitations and challenges of imaging 
 Histopathological correlation of contours for boost techniques 
 Feasibility of boost delivery 
 Integration of imaging during radiotherapy 
 
MR IMAGING 
 
There are clear benefits for the addition of MRI when contouring the prostate as 
a whole, with the improved soft tissue contrast providing better definition of the 
prostate boundary and subsequent reduced inter-observer variability [30-33]. 
 
Multiparametric Imaging 
 
The accuracy of MRI in staging prostate cancer has been extensively studied. 
Conventional MRI consists of anatomical T2 weighted images (T2W) with 
prostate cancer exhibiting low T2 signal intensity. Multiparametric MRI (mp-
MRI) includes functional data from dynamic contrast-enhanced (DCE), MR 
spectroscopy (MRS) and/or diffusion weighted imaging (DWI), which can all 
provide additional information on the tumour to improve the sensitivity and 
specificity of tumour detection [34-39]. 
 
DCE-MRI acquires images whilst contrast is administered and therefore provides 
information on the perfusion and vascular permeability of a tumour. DWI 
assesses the motion of water molecules, with tumours showing a restricted 
diffusion due to increased cellularity. This restriction of diffusion is expressed as 
the apparent diffusion coefficient (ADC) and has been found to be a predictor of 
the aggressiveness of a prostate cancer [40, 41].  MRS is a form of metabolic 
imaging that detects prostate cancer due to the lower levels of intracellular 
citrate and higher levels of choline compared to benign prostate tissue. There is 
increased sensitivity for detection of prostate cancer with the addition of MRS 
[36], however spatial resolution is poor, limiting accurate tumour delineation.  
 
Combining modalities improves the sensitivity compared to T2W images alone 
[37-39]. Pooled results from studies using the combination of T2W, DWI and 
DCE-MRI show a sensitivity of 0.74 (95% CI, 0.66–0.81) with specificity of 0.88 
(95% CI, 0.82–0.92) [42]. Of the three multiparametric modalities (DWI, MRS 
and DCE), two appear to be sufficient for maximal sensitivity and adding in the 
third modality may not be of additional benefit [43]. Current recommendations 
suggest the use of two functional MRI techniques in addition to standard T2 
weighted images [44]. Figure 2 shows an IPL on mp-MRI and PET imaging with 
an IMRT plan depicting the boost dose for the DELINEATE trial (UKCRN ID 
10309).  
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Figure 2- An IMRT delivered IPL boost to a left sided tumour with 
corresponding MRI and PET-CT imaging. Figure 2a) T2W imaging. Figure 2b) 
DW-MRI. Figure 2c) PET-CT imaging. Figure 2d) IMRT delivered boost in the 
context of the DELINEATE study- pink shading represents prostate CTV, yellow 
shading represents prostate PTV, purple shading represents IPL boost. 
 
 
 
 
 
Limitations and Challenges of MRI for delineation of IPL 
 
Accuracy  
The reported accuracy of MR imaging for IPL delineation is variable and 
dependent on a number of imaging factors as well as tumour characteristics. 
Technical factors include field strength, b values (which assess the strength of 
the gradients for DWI), signal- to-noise ratio and whether an endorectal coil 
(ERC) is used. The latter improves the spatial resolution and has been found to 
improve the sensitivity, specificity and staging accuracy of prostate cancer [45] 
but the presence of the coil causes distortion of the prostate, which limits its use 
in planning radiotherapy.  
Low signal on T2W can be seen with prostatitis, haemorrhage, post radiotherapy 
change and scarring, and distinguishing these from tumour nodules can be 
challenging. 
MRI is limited in the detection of small volume tumours e.g. <0.5cm3 [46], 
particularly those of lower Gleason score. This is due to histological 
characteristics of the tumour focus, such as the ratio of malignant epithelium-to-
stroma, which are inherently different in lesions picked up on MRI compared to 
those that are not detected [47, 48]. 
 
Interobserver Variability 
The delineated shape and size of the IPL should be consistent, aiming to 
minimise inter- and intraobserver variability. Steenbergen et al compared the 
delineated tumours using mp-MRI from six teams from three different centres 
[49]. These were compared to the histological findings from prostatectomy to 
assess the accuracy of tumour delineation and interobserver variability. Using 
the combination of T2W, DWI and DCE images, 18 out of 20 dominant lesions 
were detected by all groups. However, parts of the dominant lesion were missed 
and 66 out of 69 satellite lesions were undetected. As discussed previously, the 
clinical significance of these satellite lesions, most of which were smaller than 
0.4cm3, is unclear [15]. Although this data is consistent with the high sensitivity 
of detecting tumours with mp-MRI, there was discrepancy of the shape and size 
of the dominant lesion to be boosted. This may have an impact on local control if 
the dose to the remaining prostate were to be reduced, or focal therapy 
techniques used in isolation. However, overall there was good agreement (kappa 
statistic of 0.61) between observers.  
 
Image Interpretation 
The variation and discrepancy in IPL delineation is a significant limitation in 
allowing accurate radiotherapy boost and subsequent introduction to routine 
practice. There are scoring systems to allow a more standardised method of 
reporting, such as the PI-RADS score [44, 50] but the experience of the reporting 
radiologist remains important. A significant hurdle can be combining the 
information from multiparametric datasets. A comparison of the IPL delineation 
from DWI and DCE-MRI [51] showed a large variation in the overlap with 
particularly poor agreement in certain patients. This adds to the uncertainty of 
the IPL volume, with the same group suggesting a pathologically validated 
statistical model to predict the risk of tumour presence on a voxel level [52]. 
Computer aided delineation techniques such as this and others [53, 54] use 
quantitative features from images to assess whether each voxel is classified as 
tumour or normal tissue. Further validation is required but these programmes 
could help to reduce uncertainty in delineation and reduce interobserver 
variation [55]. 
 
Effect of Androgen Deprivation Therapy 
The timing of the imaging to be used for definition of the boost is particularly 
relevant in prostate cancer. Dominant nodules may be easily defined on initial 
diagnostic imaging, however most patients then receive ADT, which decreases 
the size of the IPL, and reduces tumour conspicuity [56]. Imaging for DIL 
delineation for radiotherapy planning could therefore be acquired prior to 
starting ADT with immediate irradiation, thus necessitating a change in the 
treatment paradigm. Alternatively, the information from pre-ADT imaging can be 
‘mapped’ onto post-ADT imaging using deformable registration techniques.  
Additionally, it is unknown whether the optimal target is in fact the pre- or post-
ADT lesion. The latter would require further investigation into the effect of ADT 
on mp-MRI images and may become clearer when the exact benefits of an IPL 
boost are confirmed. 
 
Histopathological Correlation of Contours with MRI 
The gold standard of any imaging technique is correlation with histopathology, 
however accurate comparison with imaging is extremely challenging. Even with 
studies comparing imaged IPLs with ‘whole-mount prostate’ reference histology 
there are certain limitations such as shrinkage of tissue during fixation and co-
registration errors, which may be introduced when aligning histopathology 
specimens to the equivalent imaging slice. To reduce the impact of such errors 
one group have used individualised MRI-based custom moulds to aid accurate 
co-registration of the specimens following prostatectomy [57]. 
 
Variability of tumour volume estimation 
Data shows a positive correlation between the tumour volume derived from 
histopathology and the MRI defined volume, with the accuracy of MRI estimation 
improving with a higher tumour volume [46, 58]. However, even for lesions 
greater than 0.5cm3, there is still variability [46]. Coakley et al found the MRI 
defined tumour volume ranged from 3% to 433% of the actual volume on 
histopathology [46]. However, this study looked at any Gleason grade of tumour 
in the specimen and as discussed above, Gleason grade 3+3 may be less distinct 
on MRI.  
 
Several studies show tumour volume may be under- rather than overestimated 
on MRI [59-62]. One such study comparing the volume seen on MRI compared to 
histology in 50 tumours [59], showed underestimation by mp-MRI with the 
volume being lower by a mean of 47% compared to histopathology.  
Interestingly, this group found that the underestimation was worse for lesions 
with a high Gleason score [59, 62], which has the potential to severely impact the 
outcome for these patients.  
 
Consideration of margins required to cover tumour 
Groenendaal et al found that the use of mp-MRI for IPL delineation gave a 
tumour coverage of 44-89% of the corresponding lesion on whole mount 
histopathology [60]. The addition of a margin of two voxels (approximately 
5mm) improved coverage to 85% or more. Similar results for the margin 
required have been suggested by other studies. Anwar et al identified prostate 
foci using MRS and subsequently contoured these lesions using T2W images in 
patients about to undergo prostatectomy (mp-MRI was not used) [61]. When 
compared to whole mount histopathology, they found that in order to cover the 
‘MRI undercall’ (i.e. the areas underestimated by the readers) that expansion by 
5mm at the non-capsular margin would cover 95% of the actual tumour volume.  
 
A similar study comparing MRI contouring to histopathology concluded that a 
9mm margin would be adequate to cover all 46 tumours analysed [62]. This 
differed from the studies above by looking at which margin would be required to 
cover the entire tumour. The authors suggested 9mm as the non-capsular margin 
and 3mm for the capsular margin, to take into account extraprostatic extension. 
However, the maximum Hausdorff Distance (HD), looking at the difference 
between the MR delineated lesion and histology, was significantly greater for 
high grade lesions. It must be considered that the 9mm margin suggested, 
included coverage of Gleason 6 tumours (10/46 lesions). Margins could 
therefore be stratified based on tumour characteristics, especially as in the 
absence of de-escalation to the whole prostate gland, coverage of low risk 
disease is not the objective.   For example the same study showed that a smaller 
margin of 5mm covered 73.9% of tumours, 7mm covered 93.5% of tumours.  
 
From a radiotherapy planning point of view, these studies indicate an 
intraprostatic margin of 5mm around the MRI defined IPL would be suitable [60, 
61]. A further factor to be considered is the administration of ADT, which would 
shrink the IPL and surrounding prostate, so a smaller margin may subsequently 
be appropriate.  
 
Feasibility of MRI-defined boost delivery - theoretical 
 
There have been a number of planning studies estimating the TCP, NTCP and 
investigating the factors that would make an IPL boost feasible. These are 
outlined in Table 1. 
 
Table 1: Planning Studies delivering a boost to an MRI defined IPL 
 
 
 
REFERENCE PATIENTS IMAGING TECHNIQUES RADIOTHERAPY TREATMENT FINDINGS 
Van Lin (2006) 
[63, 64] 
n=5 1.5T MRI with ERC 
T2W, MRS, DCE 
MR and CT fusion using fiducials 
IPL delineation by radiologist 
Step and shoot IMRT with SIB 
Plan 1 (boost to IPL):  
Prostate + 7mm 70Gy/35f 
IPL + 5mm 90Gy/35f 
Plan 2 (no boost to IPL): 
Prostate + 7mm 78Gy/39f 
In 5/5 patients, increased 
therapeutic ratio with boost 
plan due to a reduction in 
rectal NTCP with maintained 
TCP 
Housri (2011) 
[64] 
n=42 overall 
n=24 had 
visible IPL 
MRI with ERC 
T2W, DCE, ADC, MRS 
Treatment planning MR without ERC  in 
14/24 patients with IPL.  
Manual transfer of MRI information 
Step and shoot IMRT with SIB 
Prostate + 9mm (5mm post) 75.6Gy/42f 
IPL + 3mm 151.2Gy/42f  
Dose escalation to 151.2Gy achieved in 
12/24 and between 94.5Gy-136.1Gy in 9/24  
SIB infeasible lesions less than 
4.2mm from rectum 
SIB more feasible with greater 
hip-hip width >37.22cm 
Ost  
(2011) [24] 
n=12 T2W and/or MRS 
MR and CT fusion 
Step and shoot IMRT (3,5,7 field) compared 
to VMAT 
Prostate + 4mm D50 > 78Gy 
IPL + 0mm D50 >85Gy 
 
SIB feasible with 5,7 field IMRT 
and VMAT 
VMAT superior to IMRT for 
rectal volumes receiving 20-
50Gy  
Tree (2013) 
[28] 
n=15 T2W 
MR and CT fusion 
IPL delineation by oncologist and 
radiologist 
SBRT with SIB 
Planned for both Cyberknife and RapidArc 
IPL + 0mm 47.5Gy/5f 
Prostate + 5mm (3mm post) 36.25Gy/5f 
Boost feasible with both 
treatment methods  
If margins increased to 8mm 
(5mm post) 37/75 compared 
to 11/75 of constraints missed 
Riches (2014) 
[65] 
n=23 overall 
n=20 had 
visible IPL 
1.5T MRI with ERC 
T2W, MRS, DCE (pre-ADT) 
MR and CT fusion using fiducials  
Step and shoot IMRT 
IPL + 2mm 82Gy/37f 
Prostate + 3mm (0mm post) 74Gy 
TCP significantly higher in 
boost plan 
Rectal NTCP significantly lower 
in boost plan 
Murray  
(2014) [26] 
n=10 
 
 
1.5T MRI 
T2W, DWI, DCE 
IPL delineation by radiologist 
MR and CT fusion 
VMAT 
Prostate + 6mm 42.7Gy/7f (alternate days) 
IPL + 4mm, prescription dose increased by 
5% increments starting at 115% 
Plans with proximal SV 32.4-36.5Gy/7f 
For prostate alone plus boost- 
median SIB 53.4Gy/7f (125%) 
Rectal NTCP increased with IPL 
boost 
Feng (2015) 
[66] 
n=14 
n=7 planned 
(smaller IPL) 
1.5T MRI 
T2W 
IPL delineation by radiologist 
VMAT (dual arc) 
Prostate + 5mm (3mm post) 36.25Gy/5f 
IPL + 3mm 47.5Gy/5f 
SIB feasible in all 7 patients  
Standard rigid registration not 
clinically acceptable 
The largest of these was published by Housri et al. Nine-field IMRT plans were 
designed with the aim of delivering a total dose of 151.2Gy to the IPL without 
violating dose constraints [64]. This was possible in 12 out of 24 patients and in 
particular, they reported the distance between the IPL and rectum was 
predictive of whether high dose radiation could be delivered to the IPL, with a 
plan being infeasible with a distance of less than 4.2mm from the IPL to the 
rectum.  
 
Riches et al. planned IMRT at a dose of 74Gy to the whole prostate with an 
additional 8Gy SIB in twenty patients with an IPL identified using mp-MRI [65]. A 
planned boost was feasible in all patients whilst meeting dose constraints. 
Radiobiological modelling suggested a significant improvement for the TCP in 
the boosted plans with a significantly lower rectal NTCP for the boosted plan. 
This finding has also been reported in other studies [25, 63] and may be due to 
the redistribution of dose, including hotspots, when a boost is planned.  
 
Feasibility of MRI-defined boost delivery – clinical 
 
Acknowledging the limitations described above, and with the aspiration that MR 
imaging will continue to increase its accuracy in delineating IPLs, several 
investigators have assessed the practicalities of delivering radiotherapy with 
focal dose-escalation. There have been several studies confirming that an MRI-
planned radiotherapy boost is practically feasible, can be delivered within dose 
constraints and is possible without an increase in acute toxicity. These are 
summarised in Table 2.  
 
The studies in Table 2 have generally shown that an IPL can be selectively dose-
escalated with no obvious toxicity penalty. Further randomised studies are 
needed to confirm this hypothesis.  
 
Table 2: Clinical studies delivering a boost to an IPL. Abbreviations: CRT 
conformal radiotherapy; EORTC European Organization for Research and 
Treatment of Cancer; GU genitourinary; GI gastrointestinal; L/I/H Percentage of 
patients in Low/Intermediate/ High risk groups; QoL Quality of Life; RTOG 
Radiation Therapy Oncology Group. 
  
 
 
REFERENCE PATIENTS IMAGING RADIOTHERAPY TREATMENT SUMMARY OF TOXICITY 
De Meerleer 
(2005) [19] 
n=15 
ADT 87% 
L/I/H: not specified 
1.5T MRI with ERC  
T2W 
9/15 patients had ERC 
 
Step and shoot IMRT with SIB 
Verification with daily ultrasound 
Prostate + 7-10mm 74Gy 
IPL +0mm dose 80Gy 
Long term follow up not specified 
Acute: (RTOG) 
GI- 20% Gr2, 0% Gr3 
GU- 40% Gr2, 7% Gr3  
Singh (2007) 
[14] 
n=3                           
ADT not specified 
L/I/H: not specified 
 
3T MRI with ERC 
T2W, MRS, DCE  
MR and CT fusion using 
fiducials 
Step and shoot IMRT with SIB 
Fiducials  
Prostate + 7mm 75.6Gy/42f 
IPL +3mm dose 94.5Gy/42f 
Follow up at 18, 6 and 3 months 
2/3 patients Gr2 acute GU (RTOG) 
1/3 patients Gr1 acute GI 
All symptoms resolved at 3 months 
Fonteyne 
(2008) [67] 
n=230 overall 
n=118 had SIB 
ADT 98% 
L/I/H: 2/40/58% 
1.5T MRI with ERC 
T2W, MRS (in 49%) 
MR and CT fusion  
Step and shoot IMRT with daily ultrasound 
verification  
Prostate + 4mm dose 78Gy/38f 
IPL + 8mm dose 80Gy/38f 
Median follow up 12 months 
No increase in acute toxicity with SIB 
(RTOG) 
Miralbell 
(2010) [27] 
n=50 
ADT 66% 
L/I/H: 10/24/66% 
MRI with ERC  
T2W and DCE 
MR and CT fusion (endorectal 
balloon used for planning CT) 
Sequential hypofractionated boost, infrared 
markers. Prostate dose 64-64.4Gy  
28/50 patients 50.4Gy/28f to pelvic nodes  
21/50 patients 2f of 5-7Gy boost 
29/50 patients received 2f of 8Gy boost 
Late (at 5 years): (RTOG)  
GI- 10% Gr2, 10% Gr3 
GU- 12% Gr2, 0% Gr3  
 
 
Ippolito 
(2012) [68] 
n=40 
ADT 100% 
L/I/H: 10/42/48% 
1.5T MRI with ERC Step and shoot IMRT with SIB 
Prostate + 10mm 72Gy/40f 
IPL + 5mm 80Gy/40f 
Median follow up 19 months 
Late: (RTOG/EORTC) 
GI- 5% Gr2, 2.5% Gr3 
GU- 5% Gr2, 2.5% Gr4 
Aluwini (2013) 
[69] 
n=50 (n=14 had SIB) 
ADT 0% 
L/I/H: 60/40/0% 
1.5T MRI (no ERC) 
T2W 
MR and CT fusion using 
fiducials and foley catheter 
SBRT 
SIB in patients with visible tumour  
Prostate + 3mm 38Gy/4f (daily) 
IPL up to 44Gy/4f (daily) 
Late (at 24 months): (RTOG/EORTC) 
GI- 3% Gr2 GI, 0% Gr3 
GU- 10% Gr2 GU, 6% Gr3 GU 
No difference in toxicity with SIB 
Pinkawa 
(2012) [70, 71] 
 
n=67 (n=46 had 
SIB)ADT 17% 
L/I/H: not specified 
18F-Choline PET-CT 
IPL defined by tumour to 
background ratio of >2.0 
Prostate + 4-8mm 76Gy/38f 
IPL + 4mm (3mm post) 80Gy/38f 
Verification with daily ultrasound 
Median follow up 19 months 
No significant difference in QoL with 
addition of SIB 
Wong (2011) 
[23] 
n=71 overall 
n=51 scans positive 
ADT 24% 
L/I/H: 44/42/14% 
Indium-111-capromab 
pendetide imaging 
Co-registration with planning 
scan 
Step and shoot IMRT 
Verification with daily ultrasound  
Prostate + 6mm 75.6Gy/42f 
 
IPL + 0mm 82Gy/42f 
Median follow up 66 months 
Late:  (Mayo modification of RTOG)  
GI- 21% Gr2, 0% Gr3 
GU- 39% Gr2, 4% Gr3, 1% Gr4 
(haematuria) 
 
Integration of imaging 
 
Optimal boost delineation requires imaging to be carefully integrated into the 
planning process [65, 72]. At present, a radiotherapy planning CT provides the 
electron density data required for dose calculation and hence any additional 
boost imaging needs to be precisely co-registered with the planning CT to allow 
fidelity of the boost volume transcription. Even if imaging were to have 100% 
accuracy, if it is not precisely co-registered into the radiotherapy planning 
pathway, the IPL will not be faithfully represented. 
 
At present, the optimal method for incorporating the information from MRI, is to 
‘fuse’ the CT and MRI dataset. Although this process can be performed manually, 
software provides deformation algorithms to aid this complicated process, these 
programmes differ in the steps used to match the images and the degree of 
flexibility.  Given the variability in rectal and bladder volumes and movement of 
the prostate, as expected, deformable image registration (DIR) is more accurate 
than rigid techniques [73]. Image registration can introduce a systematic 
anatomical error although the presence of gold seeds improves this process [72, 
74]. Additional complications include MRI artefacts, limitations with the 
geometric fidelity of MRI and the distortion of the prostate seen when an ERC is 
used, all of which make accurate delineation of an IPL challenging. The 
discrepancy introduced by these MRI factors should be limited where possible, 
for example an endorectal balloon (ERB) can be used for the planning scan and 
throughout treatment to compensate for the ERC [63] but may not be practical.  
 
The ease of image registration is also dependent on whether the patient was 
scanned in the radiotherapy treatment position for the secondary image set (in 
this case MRI) with identical immobilisation including knee wedges, foot stocks 
and with the same bladder filling protocol and rectal preparation.  
 
If fusion is not possible, images are reviewed side by side to delineate the boost 
area, known as ‘visual cognitive fusion’. This will add a further uncertainty to this 
process although this manual transfer method has been used in planning studies 
[19, 64].  
 
Implementation of tumour dose-escalation 
 
Adequate margins must be added to take into account co-registration and 
delineation errors plus motion during the treatment course (intra- and 
interfraction motion). Even taking into account the margin required to cover the 
IPL adequately, given the discrepancy seen with delineation as discussed earlier, 
the optimal intraprostatic margin for the boost is unclear and is dependent on 
the mode of delivery with some studies using a 0mm margin and relying on a 
relatively shallow dose fall off within the prostate CTV [19, 23, 24, 28]. 
Treatment must be delivered accurately with the use of in-room IGRT, with 
fiducial markers as the current gold standard.  
 
Although the studies detailed here confirm the feasibility of delivering focal 
dose- escalation, with the potential for increased tumour control with decreased 
NTCP, additional information is needed. Prospective clinical trials such as the 
Phase III randomised controlled trial FLAME [75], HEIGHT (clinicaltrials.gov 
NCT01411332) and the Phase II DELINEATE (UKCRN ID 10309) and SPARC 
trials (clinical trials.gov NCT02145494) will provide the vital information on 
clinical outcome, toxicity and feasibility of boosting to decide whether focal dose 
escalation should become standard practice.  
 
PET-CT IMAGING 
 
Acquisition of Images 
 
PET-CT is a form of molecular imaging, requiring injection of a radio-labelled 
tracer which accumulates based on tissue characteristics. For prostate cancer, 
differences in choline metabolism have been most frequently exploited for PET 
imaging. In particular, research has focused on [11C] and [18F] labelled choline 
derivatives, taking advantage of the increased turnover of choline in prostate 
cancer, which is required for phospholipids in the cell membrane. Although 11C-
Choline PET-CT has the advantage of non-urinary excretion, it has a short half life 
(20 minutes) and requires an onsite cyclotron, which limits it usage. 11C-acetate 
has also been explored, however seems less favourable [76]. There are further 
investigations into other radiotracers including those targeting prostate-specific 
membrane antigen (PSMA), the synthetic amino acid analogue anti-1-amino-3-
F18-fluorocyclobutane-1-carboxylic acid (FACBC) and F-18-fluoro-5α-
dihydrotestosterone (FDHT) which targets the androgen receptor. 
PET imaging is not routinely obtained for patients being treated for prostate 
cancer, although is increasingly used to enhance staging in locally advanced or 
relapsed disease. 
 
Limitations and Challenges of PET-CT 
 
There have been several studies assessing the role of PET-CT in defining IPLs in 
prostate cancer, the majority of these use 11C- or 18F-Choline [77-81]. For 
example, a study with 11C-Choline PET-CT showed a sensitivity of 66% and 
specificity of 81% [77]. However, the uptake of lesions can be variable and the 
studies are limited by conflicting results and small sample sizes. As a result, there 
continue to be concerns over the use of PET-CT in radiotherapy planning [82]. As 
with MRI, false positives can be seen with prostatitis and inflammation 
secondary to biopsy or treatment [77]. Van den Bergh et al reported that when 
multiparametric MRI is used, there is no additional benefit of PET-CT  
[83], with the accuracy of detecting lesions dependent on the SUV used.  
 
Image interpretation 
There are two main methods that have been used for identifying the target in 
prostate cancer with PET-CT; manual interpretation of the images or the use of 
automated threshold techniques. The latter has the benefit of defining a target 
volume without observer bias and therefore maintaining consistency. However, 
there are a number of factors that will alter the SUV and therefore IPL volume 
including inhomogeneity within an IPL, lesion size and motion artefact [84]. 
Using an absolute SUV value to define the target volume does not take into 
account the variable background activity of the prostate. Therefore, the two main 
threshold methods are using a tumour-to-background ratio or percentage of the 
maximum SUV (SUVmax). Values have been derived from histopathological 
studies and are discussed further below.  
  
Spatial resolution 
PET-CT has limited spatial resolution, being unable to detect lesions smaller than 
5mm. The SUVmax of smaller tumours is less than that of larger ones [81]. The 
partial-volume effect (PVE) leads to smaller lesions either being lost or 
appearing larger (and therefore encompassing normal tissues) but dimmer [85].  
 
Histopathological correlation of delineation using PET-CT 
 
Variability of studies 
The accuracy of IPL delineation using PET-CT has been assessed by studies using 
histopathological correlation. Sensitivity and specificity can vary significantly 
depending on whether studies use voxel, segments or whole prostate level of 
analysis as the area of interest. Studies also vary depending on the patient 
population, the standardised uptake value (SUV) threshold used and the 
acquisition of images. As noted earlier, there are limitations of these 
histopathological studies, which must be considered when interpreting results. 
Amongst the issues to be considered are the accuracy and type of pathology 
(biopsy or whole mount specimens), the optimal timing of the imaging following 
tracer injection, and the most appropriate segmentation or thresholding level for 
defining the IPL. 
 
Timing of PET Imaging 
Kwee et al analysed the change in maximum SUV (SUVmax) in malignant and 
benign areas in prostate cancer using additional delayed scanning at one hour 
[78]. SUVmax for malignant areas increased from the initial to delayed scan 
whereas the mean SUVmax for benign areas decreased. The difference between 
areas marked as ‘dominant malignant’ and ‘probably benign’ was only 
statistically significant on delayed imaging with the mean malignant-to-benign 
ratio increasing from 1.4 on the initial images to 1.8 on the delayed images. The 
additional challenge of using delayed imaging with this modality however, is that 
18F-Choline is renally excreted with accumulation of radioactivity within the 
bladder, which can complicate image interpretation of the prostate base.  
 
Methods for IPL delineation 
A mean tumour-to-background ratio of approximately 2 has been identified in 
several studies as a method for IPL delineation [77, 78, 81] and was used by 
Pinkawa et al for delineation of a clinically delivered boost volume [70]. In this 
study, definition of the IPL was based on a slightly increased tumour to 
background ratio of >2 in order to increase specificity, although this would lead 
to a decreased sensitivity with smaller tumours excluded.  
An autocontour method based on 60% of the maximum SUV (SUV60) has been 
reported by several groups as having the best correlation with histopathology 
[79, 80, 86]. However, in these studies, the SUV60 was not found to be 
significantly better when compared to the other threshold contours [80, 86]. It is 
also unclear as to which correlation indices are best to compare contours and 
whether the dice similarity co-efficient (DSC) and Youden Index (YI) adequately 
assess the clinical significance of overlap. Therefore, although SUV60 had the 
highest correlation indices (as per DSC and YI), this requires prospective clinical 
validation before implementation.  
As the percentage of SUVmax threshold increases, specificity increases but 
sensitivity decreases as used by Pinkawa et al to increase the specificity for dose-
escalation [20].  
 
Comparison of PET-CT with MRI for delineation accuracy 
Chang et al [86] used reference contours defined from prostatectomy pathology 
in 21 patients to compare the accuracy of manual contours from 11C- Choline 
PET-CT to manual contours using DW-MRI. They found that PET-CT had 
significantly better correlation to the reference contours compared to T2W/DW-
MRI. A limitation of this study however, was that multiparametric sequences of 
DCE-MRI or MRS were not included, as per the Barentz recommendations [44] 
therefore the comparison did not include the optimal set of MR images. This 
group also found, as previously shown [79, 80], that the SUV60 had the best 
correlation to the reference contours and in fact performed significantly better 
compared to manual delineation by a radiologist using the PET-CT.  
 
Feasibility of Boost Delivery using specific tracers 
 
There have been several studies investigating the feasibility of delivering a dose-
escalated boost to the delineated IPL using various specific PET tracers. The 
clinical study by Pinkawa is outlined in Table 2, with planning studies 
summarised in Table 3. 
 
 
Table 3: Planning studies delivering a boost to a PET-CT defined IPL 
  
REFERENCE PATIENTS IMAGING TECHNIQUES RADIOTHERAPY TREATMENT FINDINGS 
Kuang (2015) [25] n=30 18F-Choline PET/CT 
Boost defined by 60% and 70% of 
SUVmax threshold (labelled IDLSUV60%  
and IDLSUV70% respectively) 
 
VMAT 
Plan1: 
Prostate + 3-6mm 79Gy/39f 
Plan 2: 
Prostate + 3-6mm 79Gy/39f 
IDLSUV60%  + 3-6mm 100Gy/39f 
IDLSUV70% + 3-6mm 105Gy/39f 
SIB feasible in all patients  
TCP significantly higher in boost 
plan 
Slightly lower rectal NTCP in boost 
plan 
Seppala (2009) [22] n=12 11C-Acetate PET/CT 
Co-registration with planning scan 
SUV of 2.0 used for IPL delineation 
Step and shoot IMRT 
Plan 1: 
Prostate + 6mm 77.9Gy/41f 
Plan 2: 
Prostate + 6mm 72.2Gy/41f 
IPL + 6mm 77.9Gy-90Gy/41f 
TCP increased for all boost plans 
Average dose of 82.1Gy to IPL gave 
the highest probability of 
uncomplicated control 
Chang (2012) [21] 
 
n=8 11C-Choline PET/CT 
Co-registration with planning scan 
Boost defined by 60% and 70% of 
SUVmax threshold (labelled SUV60% and 
SUV70% respectively) 
Step and shoot IMRT 
Plan 1 (standard): 
Prostate + 6mm 78Gy/39f 
Plan 2 (boost plan): 
Prostate + 6mm 78Gy/39f 
IPL (SUV60%) + 6mm 84Gy/39f 
IPL (SUV70%) + 6mm 90Gy/39f 
Plan 3 (boost plan, de-escalation to prostate): 
Prostate + 6mm 72Gy/39f 
IPL (SUV60%) + 6mm 84Gy/39f 
IPL (SUV70%) + 6mm 90Gy/39f 
SIB feasible in all patients 
TCP significantly higher for both 
boost plans compared to standard 
plan 
No significant difference in TCP 
comparing boost plans 2 and 3 
No significant difference in rectal 
NTCP for all three plans 
 
11C- Choline PET-CT 
Chang et al [21] generated IMRT plans for 8 patients using the contouring 
methods described above [80] to deliver two boost doses within a single plan. 
PLAN78-90 delivered 78Gy, 84Gy and 90Gy and PLAN72-90 delivered 72Gy, 84Gy 
and 90Gy to the whole prostate, SUV60% and SUV70% respectively. All plans were 
feasible whilst meeting dose constraints, with the rectal NTCP being non-
significantly lower in the boost plan. Both boost plans had a significantly higher 
TCP for the PET defined volume (TCPPET) and the prostatectomy specimen 
defined volume (TCPpath) compared to the standard plan where 78Gy was 
planned to the whole prostate alone. However, the risk of de-escalating the non-
DIL prostate was demonstrated for one of the patients where the TCPpath was 
lower in the PLAN72-90 boost plan compared to PLAN78. Overall, using the 
histopathology from prostatectomy, they were able to demonstrate increased 
population TCP with this method. . 
 
18F-choline PET-CT 
Kuang et al concluded 18F-choline PET-CT can be used to localise a boost volume 
for VMAT plans [25]. Using a similar method to Chang, radiotherapy plans had a 
two dose level boost of 105Gy defined using the 70% of the SUVmax threshold 
(labelled IDLSUV70%) ‘nested’ inside a larger boost of 100Gy defined by 60% of the 
SUVmax (labelled IDLSUV60%) with the aim of delivering the higher dose to the area 
of greater tumour specificity, whilst maintaining a dose of 79 Gy to the whole 
gland. They reported a higher TCP and a slightly lower rectal NTCP with the 
addition of a boost compared to a plan delivering 79Gy alone to the prostate.  
 
11C-acetate PET-CT 
11C-acetate PET-CT was used by Seppala et al to define the IPL using an absolute 
SUV of 2.0 in a planning study of 12 patients [22]. They similarly confirmed an 
improved TCP with IMRT plans delivering a SIB up to 90Gy, without increasing 
the NTCP. However, a meta-analysis has concluded that 11C-acetate should not be 
used for IPL localisation due to poor sensitivity and specificity [76]. 
  
Just as for MRI planning, the higher TCP seen with dose-escalation to the IPL is 
on the assumption that the imaging perfectly defines the target. Dose modelling 
has demonstrated that any additional benefit in TCP due to a SIB will be 
dependent on the sensitivity of imaging [87]. 
 
Integration of Imaging 
 
With combined PET-CT images, the process of image registration is simpler 
compared to that needed for CT-MRI fusion. However, the PET imaging 
component is acquired in several phases so there will still be some discrepancy 
with bladder and bowel filling and prostate position. PET-CT images are 
obtained without the distortion from ERC discussed previously and can be used 
in patients with contraindication to MRI. 
 
Implementation of Tumour Dose-escalation 
 
The importance of accurate delivery with IGRT has already been discussed. The 
optimal technique for tumour segmentation and delineation with PET-CT is not 
yet clear. Further investigation and validation of proposed methods such as 
tumour to background and SUV60 is required with rigorous histopathological 
assessments and robust follow up of outcomes. An expansion margin may be 
additionally required to cover the IPL adequately, similar to those described 
above for MRI [60-62]. 
 
 
OTHER IMAGING 
 
An Indium-111-capromab pendetide scan (ProstaScint) uses an FDA-approved 
monoclonal antibody to target upregulated prostate-specific membrane antigen 
(PSMA) receptors on prostate cancer cells. This tracer shows much promise in 
both the staging of de novo prostate cancer and in detecting recurrent disease. It 
has been used in a prospective trial to localise an IMRT planned boost (see Table 
2) [23]. Results including biochemical control and toxicity were reported as 
favourable but further studies are needed to confirm the accuracy of localisation. 
The study used a prostate/muscle ratio of signal intensity 3:1, but similar to the 
choline studies, the optimal threshold for contouring would need further 
investigation. There are conflicting results on the reliability of localising prostate 
cancer [88, 89] however research continues into other agents that target PSMA. 
 
FUTURE PERSPECTIVE 
 
Combining imaging modalities 
 
A combination of imaging may be helpful, which would optimally use one 
modality with high sensitivity and a second with high specificity. Imaging 
techniques are constantly evolving and refinements in MR or PET technique may 
increase our confidence in IPL delineation. Combining several modalities may 
further increase the fidelity of our contouring.   
 
Patient stratification 
 
The studies discussed here have demonstrated the technical feasibility of dose-
escalation to an IPL but follow up is required from randomised prospective trials 
to determine the benefit and effect on toxicity.  There is significant heterogeneity 
in prostate cancers, which will complicate the decision as to whether a boost is 
required and the appropriate dose to be used. Tumours of the same size can have 
a different risk of relapse dependent on tumour biology and other pathological 
predictive factors [90]. Ideally, utilising information from a combination of 
sources including imaging, pathology and biomarkers will allow stratification of 
patients to reflect the heterogeneity of tumours in the radiotherapy dose 
distribution. The use of hypoxic markers can be considered for dose-escalation 
combined with prognostic markers for personalised radiotherapy. 
 
In addition, imaging patients during a radiotherapy course for an early response 
assessment may predict those likely to fail biochemically, identifying patients 
who would benefit from further dose-escalation. This escalation could then be 
given using adaptive radiotherapy to the existing plan or as a hypofractionated 
boost at the end of treatment. Further research is ongoing to search for such 
imaging biomarkers.  
 
Differential Dose 
 
Rather than having a single dose to the entire IPL, several planning studies 
discussed here have demonstrated how more than one boost dose can be 
delivered to the IPL using PET-CT [21, 25]. This can maintain the maximum dose 
within the area of higher specificity, whilst having a fall off for the dose closer to 
organs at risk. The same approach could be used with mpMRI, based on 
guidelines for the interpretation of MR imaging [44] or validated models which 
predict tumour presence [52]. This model by Groenendaal et al for example 
suggests three levels; a GTV, a high-risk CTV and low-risk CTV (i.e. standard 
prostate dose) based on high, intermediate and low tumour probability 
respectively.  Alternatively a multiple dose level approach could be considered 
when imaging is used to identify a sub-volume of more aggressive or radio-
resistant disease within the IPL. 
 
MRI workflow 
 
MR currently is the preferred modality for boost delineation. As there are some 
limitations of image registration with CT, an MRI only workflow would eliminate 
this systemic error. Planning using MRI images alone has its own challenges, 
including the lack of electron density information required for dose calculations 
and distortion, however there are several methods described and being 
developed for this such as ‘pseudo’ or  ‘synthetic’ CT [91, 92]. 
IGRT improves accuracy of radiotherapy delivery, but most commonly used 
methods, such as CBCT and gold seeds do not take into account intra-fraction 
movement, which contributes to the margin to be added and impacts the 
therapeutic ratio. Imaging during treatment further improves the accuracy of 
treatment, allowing gating or adaptation. Development of combinations of a 
linear accelerator or cobalt machine with on board MRI imaging [93, 94] may 
further improve inter- and intra-fraction imaging. Furthermore, acquisition of 
MR images during treatment may mean the boost regions could be directly 
visualised during beam delivery, increasing accuracy, calculation of delivered 
dose and facilitating adaptive planning strategies.  
 
What is the objective of imaging a dominant lesion? 
 
Prostate cancer comprises a wide spectrum of disease, ranging from what could 
be considered a variant of normal ageing (organ confined Gleason 6 disease) to a 
life-limiting aggressive disease. Current stratification is inadequate to identify 
patients who would most benefit from dose-escalated local treatment. For those 
with low to low-intermediate risk disease, conventional doses are sufficient to 
cure the vast majority of patients and a boost is unlikely to be required. For those 
with intermediate or high risk disease, a boost to the IPL may increase TCP with 
little or no effect on toxicity. In this case, the optimal imaging modality may not 
need to be sensitive to low risk Gleason 6 disease, which will be adequately 
treated with conventional dose. A deficit of the current literature is the lack of 
understanding of the correlation between imaging findings with high risk 
pathology only. In addition, mpMRI and PET imaging have not been robustly 
compared, to help determine the optimal imaging modality for IPL delineation.  
 
If the identification of the IPL is a prelude to de-escalating or even not treating 
the rest of the prostate gland, then there is still some way to go before we can be 
confident that our chosen imaging modality identifies all intra-prostatic disease 
or indeed that which requires treatment.  
 
CONCLUSION 
Dose-escalation to an MRI or PET-CT defined IPL is theoretically feasible, but 
further studies are needed to confirm the optimal imaging techniques which will 
faithfully represent the IPL in the radiotherapy planning process. Early clinical 
data suggest acceptable toxicity when DIL boosts are delivered with 
sophisticated radiotherapy techniques and state-of-the-art IGRT. Prospective 
clinical data is required to confirm which patient groups would benefit and to 
quantify any improvement in the therapeutic index. 
 
EXECUTIVE SUMMARY 
 
Rationale behind intraprostatic boost 
 Dose-escalation to the whole prostate improves biochemical control but 
at the expense of increased toxicity 
 Local recurrence occurs at the site of the primary tumour, therefore a 
boost to the IPL may improve the therapeutic ratio 
 
MRI for IPL delineation 
 Although mp-MRI improves the accuracy of tumour detection, there are a 
number of limitations including a mismatch between different MRI 
techniques, false positive findings and the effect of ADT on imaging 
 The interpretation of MR images is operator and training dependent and 
prone to interobserver variation, even in the presence of published 
scoring systems 
 Histopathological correlation studies indicate that IPL volumes delineated 
by MRI tend to underestimate the true tumour volume, with studies 
suggesting a margin of 5-9mm to cover the ‘undercall’  
 Clinical and planning studies have shown that a boost to an IPL is feasible, 
with acceptable levels of toxicity and the potential to improve the TCP 
 The IPL must be accurately transferred through the radiotherapy 
planning process by using the fusion of images, and treatment must be 
delivered using high quality IGRT 
 
PET-CT for IPL delineation 
 PET-CT can be used for tumour delineation but sensitivity and specificity 
is variable, with fewer studies confirming histopathological correlation 
 Image interpretation is variable; IPL delineation can be manual or 
automated, with methods used to define the IPL based on a percentage of 
the SUVmax or a tumour to background ratio 
 The limited clinical and planning studies indicate that a boost is feasible 
to a PET-CT defined IPL, with the possibility of using differing SUV 
thresholds to varying dose levels 
 The IPL must be faithfully represented throughout the planning process 
and treatment delivered accurately with IGRT 
 
Future Perspectives 
 Data is needed from prospective trials to confirm the benefits of 
delivering a boost to the IPL and to confirm the best imaging, contouring 
methods, boost dose and radiotherapy techniques 
 A combination of imaging, pathology and biomarkers could be used to 
stratify patients and individualise treatment to identify those patients 
who will benefit from focal dose-escalation  
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